Press Release
Astellas Announces Personnel Changes and Organizational ChangesTokyo, August 24, 2017 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka) today announced the personnel changes and organizational changes as below.
Personnel Changes effective on October 1, 2017
Name
New Title
Current Title
Catherine J. Wertjes
Head of
Ethics & Compliance (No change: only Japanese organization name will be changed)
Head of
Ethics & Compliance
Hideki Yamanaka
Vice President, Ethics & Compliance,
Japan and Asia Oceania
Vice President, Ethics & Compliance, Japan and East Asia
Emi Ito
Vice President, Sales Capability
Development & Training, Japan Sales & Marketing
Senior Director, Product Marketing,
Japan Sales & Marketing
Tomonobu Koizumi
Staff Executive Director, Innovation & Incubation Research Labs., DDR
Vice President, Regenerative Medicine Labs., DDR
Atsunori Kaibara
Staff Executive Director, Japan-Asia Clinical Pharmacology, Development
Senior Director, Japan-Asia Clinical Pharmacology, Development
DDR: Drug Discovery Research
Organizational Changes effective on October 1, 2017
To further increase the productivity for regenerative medicine research, Regenerative Medicine Labs. will be reorganized and integrated into Astellas Institute for Regenerative Research (AIRM). AIRM will be a major function of regenerative medicine research in Astellas group. Astellas continues to pursue joint research and collaborations in Japan as ever.
Sales Capability Development & TrainingThe human resources functions (talent management, labor administration, compensation and benefit, diversity & inclusion, etc.) at Japan Sales & Marketing will be transferred to Human Resources and this department will focus on the training function specific to Japan Sales & Marketing. In accordance with this change, "Human Resources Development" will be renamed "Sales Capability Development &
Training".
### About AstellasAstellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. We focus on Urology, Oncology, Immunology, Nephrology and Neuroscience as prioritized therapeutic areas while advancing new therapeutic areas and discovery research leveraging new technologies/modalities. We are also creating new value by combining internal capabilities and external expertise in the medical/healthcare business. Astellas is on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at www.astellas.com/en.
Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.
Contacts for inquiries or additional information:Astellas Pharma Inc. Corporate Communications
TEL: +81-3-3244-3201 FAX: +81-3-5201-7473
Astellas Pharma Inc. published this content on 24 August 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 24 August 2017 05:07:03 UTC.
Original documenthttps://www.astellas.com/en/corporate/news/pdf/170824_1_Eg.pdf
Public permalinkhttp://www.publicnow.com/view/FDEEDD5E617111A403D2E84EB66037176D636DAA